Rinvoq Approved for Active Non-Radiographic Axial Spondyloar

The FDA has approved Rinvoq (upadacitinib) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Related Keywords

Thomas Hudson , Assessment In Spondyloarthritis International Society , Drug Administration , Spondyloarthritis International Society , Patient Global Assessment , Disease Activity , Bath Ankylosing Spondylitis Functional Index , Ankylosing Spondylitis Quality , Accessed October ,